CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $) In Thousands	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash flows from operating activities:
Net loss	$ (21,008)	$ (50,998)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	4,052	4,349
Common shares contribution to 401(k)	1,046	905
Share-based compensation expense	5,598	3,743
Accrued interest on interest bearing obligations	762	260
Revaluation of warrant liabilities	(3,349)	(4,811)
Warrant modification expense	0	4,500
Amortization of discount on long-term debt	1,019	0
Unrealized loss on foreign currency exchange	1,136	0
Unrealized gain on foreign exchange options	(157)	0
Other non-cash adjustments	47	19
Changes in assets and liabilities affecting cash:
Trade and other receivables, net	5,964	(713)
Prepaid expenses and other assets	(1,850)	(615)
Accounts payable and accrued liabilities	(1,305)	2,217
Deferred revenue	(13,008)	(1,510)
Other liabilities	78	(256)
Net cash used in operating activities	(20,975)	(42,910)
Cash flows from investing activities:
Purchase of property and equipment	(2,586)	(277)
Net cash used in investing activities	(2,586)	(277)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	20,102	0
Proceeds from issuance of common shares	12,435	40,638
Payment for modification of warrants	0	(4,500)
Net cash provided by financing activities	32,537	36,138
Effect of exchange rate changes on cash	(573)	0
Net increase (decrease) in cash and cash equivalents	8,976	(7,049)
Cash and cash equivalents at the beginning of the period	37,304	23,909
Cash and cash equivalents at the end of the period	45,707	16,860
Supplemental Cash Flow Information:
Cash paid for income taxes	15	16
Non-cash investing and financing activities:
Discount on long-term debt	(8,899)	0
Issuance and extinguishment of warrant liabilities	0	1,767
Interest added to principal balance on Novartis note	170	164
Interest added to principal balance on Servier loan	$ 330	$ 0